We subsequently analyzed their expression levels in 693 glioma samples from CGGA database, and LBX2-AS1 was the only one that was differentially expressed between primary and recurrent cases of both low-grade glioma (WHOII, WHOIII) and GBM (Figure 1C). Here, LBX2 is linked to central nervous system cancer.